A biopharmaceutical company trading at a deeply discounted 5.3x forward earnings with a 4-to-1 favorable reward/risk ratio is blocked by a confirmed downtrend including a hard death-cross signal, three consecutive annual earnings misses, a dividend payout ratio at 231% of net income, and financial leverage—creating a value opportunity that cannot be acted on until the price trend and earnings execution reverse.
Thesis pillars
- Deep Value Attractive Upside→Stable
- Consecutive Earnings Misses↓Deteriorating
- Confirmed Downtrend Death Cross↑Improving
- +2 more pillars — see the Why tab for full reasoning
Grifols, S.A. (GRFS) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - General
Wait for pullback to $7.46. BUY gates pass at $7.58, but leverage penalty (D/E 1.2): -0.5 and value-trap signals (2/5): Margin compression (op margin -30.2%), Material insider selling (18 sells, 0.14% of cap) argue for a more patient entry. Engine's entry $7.46 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies,... Read more
Wait for pullback to $7.46. BUY gates pass at $7.58, but leverage penalty (D/E 1.2): -0.5 and value-trap signals (2/5): Margin compression (op margin -30.2%), Material insider selling (18 sells, 0.14% of cap) argue for a more patient entry. Engine's entry $7.46 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 61. Earnings in 1 day. Wait until post-earnings. Score 5.8/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 1d<=7d. Suitability: moderate.
Recent developments
updated 2026-07-27Recent Developments — Grifols, S.A.
Latest news
- NEWS Grifols (BME:GRF) Starts Phase 3 Trials As The Undervalued Case Faces A Fresh Test - simplywall.st — simplywall.st positive
- NEWS Earnings Preview: Grifols to Report Financial Results on July 28 - Moomoo — Moomoo neutral
- NEWS GRFS|Grifols SA|Price:7.580|Chg%:+0.040 - TradingKey — TradingKey neutral
- NEWS Grifols (GRFS) Rebounds 4.95% as Stock Tests Key Resistance Near $8 - Quality ETF - dars.gov.et — dars.gov.et positive
- NEWS Grifols Soars As Flagship Drug Trials Spark Rally - TipRanks — TipRanks positive
Generated 2026-07-27T12:57:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $7.46. BUY gates pass at $7.58, but leverage penalty (D/E 1.2): -0.5 and value-trap signals (2/5): Margin compression (op margin -30.2%), Material insider selling (18 sells, 0.14% of cap) argue for a more patient entry. Engine's entry $7.46 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 61. Earnings in 1 day. Wait until post-earnings. Target $9.24 (+21.9%), stop $7.06 (−7.4%), A.R:R 2.4:1. Score 5.8/10, moderate confidence.
Take-profit target: $9.24 (+21.8% upside). Target $9.24 (+21.9%), stop $7.06 (−7.4%), A.R:R 2.4:1. Stop-loss: $7.06.
Leverage penalty (D/E 1.2): -0.5; Value-trap signals (2/5): Margin compression (op margin -30.2%), Material insider selling (18 sells, 0.14% of cap).
Grifols, S.A. trades at a P/E of 11.0 (forward 5.2). TrendMatrix value score: 9.1/10. Verdict: Buy (Wait for Entry).
21 analysts cover GRFS with a consensus score of 3.8/5. Average price target: $11.
What does Grifols, S.A. do?Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of...
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.